Embolic Stroke of Undetermined Source Clinical Trials
3 recruiting trials for Embolic Stroke of Undetermined Source. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Embolic Stroke of Undetermined Source clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 / Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Asan Medical Center (1), University of East Anglia (1), Inha University Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is PFO closure (procedure, 1 trial), followed by Empagliflozin 10 MG.
Track Embolic Stroke of Undetermined Source trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Prospective Registry of Elderly ESUS With PFO
Patent foramen ovale (PFO) is associated with an increased risk of stroke. PFO-closure was effective in preventing stroke in young stroke patients less than age 60 presented as an...
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients...
Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF. Whilst there has been...
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Embolic Stroke of Undetermined Source, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Embolic Stroke of Undetermined Source, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Embolic Stroke of Undetermined Source, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.